This line is cryopreserved and requires cryorecovery.
- Model #
An inducible cre deleter under the control of the prospero homeobox 1 (Prox1) promoter.
Cre recombination is inducible via administration of tamoxifen.
Allows specific and temporally controlled cre-loxP recombination (gene inactivation/activation) in Prox1-expressing tissues, including lymphatic endothelia.
Efficient recombination is observed during all developmental stages (embryonic, postnatal) and in adults.
Genetic Background: C57BL6
The Prxo1-creERT2 mouse was developed in the laboratory of Taija Makinen at the London Research Institute. A cDNA encoding tamoxifen inducible Cre recombinase (CreERT2) followed by SV40 polyadenylation signal was introduced into the start codon of Prox1 in BAC clone RP23-190F21 using homologous recombination in bacteria. Founder lines were backcrossed to C57BL/6. Taconic received embryos from CRT in 2015.
Access to this model requires execution of a Limited Breeding Agreement. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users.
Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.